This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and ...
Alume appoints Daniel Bradbury as Exec. Chair and adds Drs. Geoffrey Ling and Craig Venter, advancing fluorescence from ...
Analysts think the shares look cheap. The post This biotech says it will turn over more than $1 billion next year. Is it undervalued? appeared first on The Motley Fool Australia.
The National Security Commission on Emerging Biotechnology is visiting Pittsburgh to talk about how biotechnology and artificial intelligence will play a role in the city.
Amazon S3 on MSN
Is AI going to take jobs from doctors?
Biotech investor Robert Nelsen made a bold prediction at a live recording of STAT’s "Readout LOUD" podcast last month in San ...
Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...
Healthcare Investors reported an 8.43% NAV return for Q4 2025. Read the full analysis for insights on sector strategy and ...
Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...
PVI secures top workplace recognition again, reflecting its high-trust culture and commitment to accelerating success ...
Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” ...
Preemptive cyber defense team releases list of 100+ high-value targets We expect the targeting list to evolve rapidly ...
Was Hims' Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what's happening with Moderna and FDA? Find out on "The Readout LOUD" podcast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results